Primary prevention of ASCVD and T2D: new Endocrine Society guidelines

  • Rosenzweig JL & al.
  • J Clin Endocrinol Metab
  • 31 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • New Endocrine Society clinical practice guidelines address primary prevention of atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes (T2D) in individuals at risk.
  • Cosponsored by the American Diabetes Association and the European Society of Endocrinology.

Key recommendations

  • Regularly screen and identify individuals age 40-75 years at metabolic risk for ASCVD and T2D by measuring BP, waist circumference, fasting lipid profile, and blood glucose.
  • In those at risk, apply a 10-year global risk assessment for ASCVD or coronary heart disease to determine therapy targets for reducing apolipoprotein B-containing lipoproteins.
  • Hypertension should be treated to guideline targets.
  • Individuals identified with prediabetes should be tested at least annually for progression to T2D and referred to intensive behavioral counseling programs.
  • Lifestyle management should be the first priority for primary prevention of ASCVD and T2D.
  • Behavioral programs should include heart-healthy dietary pattern, sodium restriction, daily walking, limited sedentary time, and structured physical activity program.
  • Those with overweight/obesity should aim for ≥5% reduction in initial body weight in the first year.
  • Behavior changes should be supported by a comprehensive program led by trained interventionists and reinforced by clinicians.
  • Pharmacological therapy can be added to lifestyle modification if recommended goals are not achieved.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.